Indexa Markets Brief — Wednesday 1 April

10 stories · Sent Wednesday, 1 April 2026

Indexa

Morning Markets Brief

Wednesday, 1 April 2026

Today’s top story: US gasoline hits $4 a gallon for first time since 2022 as Iran war tightens oil supply. 10 stories analysed across the financial press, with market implications.

Commodities • 11 outlets

US gasoline hits $4 a gallon for first time since 2022 as Iran war tightens oil supply

The US national average gasoline price reached $4.02 a gallon on Tuesday, according to AAA data, the highest level since August 2022. The move caps a month of…

Why it matters: The $4/gallon threshold is a politically visible accelerant to the consumer sentiment deterioration already documented in late March. If higher-income households, which were already turning negative…

Read full analysis →

M&A • 9 outlets

McCormick and Unilever food arm combine in $44.8bn deal

McCormick, the US spice and condiments group, has agreed to combine with Unilever's food division in a transaction valuing the unit at $44.8bn. Unilever will…

Why it matters: The reverse Morris Trust structure means Unilever retains majority ownership in the combined food entity, which limits its ability to fully deploy the proceeds into personal care and home care M&A in…

Read full analysis →

Markets • 7 outlets

OpenAI closes $122bn funding round at $852bn valuation

OpenAI has closed a $122bn funding round, raising its valuation to $852bn and cementing its position as one of the most highly valued private companies…

Why it matters: The inclusion of an ETF manager in the round creates a listed vehicle with direct OpenAI exposure before any IPO. This draws retail capital into a pre-IPO position via the ETF wrapper, which…

Read full analysis →

Markets • 5 outlets

Micron shares down 30% since blowout earnings as DRAM spot prices retreat

Micron's stock has fallen roughly 30% since its strong earnings report on 18 March, with a further 10% decline recorded in the days that followed. The sell-off…

Why it matters: The 30% post-earnings decline in MU reflects two compounding pressures: DRAM spot price softening as a leading indicator for contract price deterioration, and the Google TurboQuant overhang on…

Read full analysis →

Markets • 5 outlets

Oracle cuts thousands of jobs as AI investment drives workforce restructuring

Oracle conducted a large-scale reduction in force on Tuesday, with senior employees posting publicly that engineers, architects, operations leaders and…

Why it matters: Oracle's move to fund capex through both workforce reduction and $25bn in bond issuance confirms that enterprise AI infrastructure is now a balance-sheet-intensive business where labor is the swing…

Read full analysis →

Markets • 4 outlets

Novo Nordisk launches discounted Wegovy subscription to compete with Eli Lilly

Novo Nordisk has introduced a subscription pricing programme for Wegovy in the United States targeting patients who pay out of pocket, offering savings of up…

Why it matters: Novo's decision to distribute Wegovy through Hims & Hers directly validates HIMS as a GLP-1 distribution channel, removing the regulatory and partnership overhang that has weighed on the stock.…

Read full analysis →

Markets • 3 outlets

Nvidia takes $2bn stake in Marvell in latest AI ecosystem bet

Nvidia is investing $2 billion in Marvell Technology, pairing a financial stake with a strategic partnership. The move extends Nvidia's pattern of equity…

Why it matters: Nvidia taking an equity stake rather than purely commercial contracts with Marvell converts a vendor relationship into a balance-sheet alignment. This increases Marvell's switching costs and makes it…

Read full analysis →

M&A • 3 outlets

Biogen acquires Apellis Pharmaceuticals for $5.6bn cash

Biogen has agreed to acquire Apellis Pharmaceuticals in an all-cash transaction valued at approximately $5.6 billion. The deal broadens Biogen's presence in…

Why it matters: Biogen's $5.6bn all-cash bid for Apellis, following Merck's $6.7bn cash acquisition of Terns, confirms that large-cap pharma business development is accelerating into rare and orphan disease targets…

Read full analysis →

M&A • 3 outlets

Eli Lilly acquires Centessa for up to $7.8bn to enter narcolepsy market

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal worth up to $7.8 billion, gaining a portfolio of orexin receptor 2 agonists designed to…

Why it matters: Lilly's entry into orexin biology creates direct competitive pressure on Jazz Pharmaceuticals, which holds the incumbent narcolepsy franchise with Xyrem and Xywav. A well-capitalized Lilly commercial…

Read full analysis →

M&A • 3 outlets

Allbirds sold to American Exchange Group for $39 million

American Exchange Group has agreed to acquire sustainable footwear brand Allbirds for $39 million, a fraction of the nearly $393 million the company raised…

Why it matters: The $39 million exit price for Allbirds, against a $393 million IPO raise and $2.2 billion peak valuation, establishes a floor comp for other pandemic-era DTC consumer brands still trading on…

Read full analysis →

This is an archived issue of the Indexa Morning Markets Brief.

Visit Indexa • Subscribe

← 31 Mar 2 Apr →

Get this in your inbox every morning

The top financial stories of the day, with market implications and source analysis. Free forever.